Please assess the completion status of the following clinical trial:

Trial Title: NSAIDs in Sciatica NSAIDS IN SCIATICA

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Age ≥ 18 years~* Radiating pain below the knee with a severity score of ≥4 on a 0-10 (NRS) in the previous 24 hours~* Signs of nerve root/spinal nerve involvement as indicated by at least one of the following features; myotomal weakness, dermatomal sensory disturbances (e.g. sensory loss, self-reported tingling/numbness), diminished reflexes, radiating pain exacerbation by SLR~Exclusion criteria:~* Not able to read or speak Norwegian.~* Unlikely to adhere to treatment and/ or complete follow-up (e.g ongoing serious psychiatric disease, drug abuse, plans to move)~* Sciatica of known cause other than disc herniation or degenerative stenosis.~* Neurogenic claudication, i.e. pain in the legs on walking or standing that resolves with sitting down or lumbar flexion.~* Symptoms indicating immediate surgery: cauda equina syndrome or a progressive large paresis.~* Women who attempt to conceive, are pregnant or breastfeeding.~* Previous episodes of asthma, urticaria or allergic-type reactions after taking aspirin or other NSAIDs.~* Active or history of peptic ulceration, gastrointestinal bleeding, or perforation.~* Use of drugs known to increase upper gastrointestinal adverse events in combination with Naproxen: anticoagulants, aspirin (acetyl salicylic acid), serotonin reuptake inhibitors and systemic corticosteroids.~* Hepatic enzyme (ASAT/ALAT) values above 1,5 x upper limit of normal (ULN)~* Renal function tests (creatinin/eGFR) outside normal range~* Congestive heart failure, established ischaemic heart disease, peripheral arterial disease, and/or cerebrovascular disease.~* Known hypersensitivity to Naproxen or any of the excipients (lactose, maize starch, povidone, sodium starch glycolate, talcum, magnesium stearate, polysorbate 80)~* Ongoing treatment with aspirin, systemic corticosteroids, diuretics, ACE-inhibitors, lithium and anticoagulants~* Scheduled for spinal surgery prior to end of study~* Reservation against intake of gelatine (the capsules contains gelatine, which among other things is produced by ingredients from pigs)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Naproxen (Type: EXPERIMENTAL): Naproxen 500 mg twice daily
- Placebo (Type: PLACEBO_COMPARATOR): Placebo 1 tablet twice daily

Based on this trial design, predict the completion outcome and termination type (if applicable).